# Coherent Biopharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/coherent-biopharma

- Industry: Pharmaceuticals
- Headquarters: Suzhou, China
- Website: www.coherentbio.com
- Latest round: Series B (May 12, 2023)
- Investors on record: 14

## About

Established in 2016 and based in Suzhou, China, Coherent Biopharma, Ltd. is a dual-targeted ligand-coupled drug bi-XDC company dedicated to the development and industrialization of dual-targeted XDC drugs. The company's drug development center covers an area of 3600 square meters, management team includes two national major talent introduction project entrants and one high-level talent of Jiangsu Province for innovation and entrepreneurship. In 2020, The company's drugs CBP-1008, and CBP-1018 received US FDA clinical clearance and Chinese NMPA clinical trial standards. The company has completed 4 rounds of funding as of 2023.

The company utilizes the BEST™ technology platform, the C-PROTAC technology platform, and the chronic disease technology platform for the development and industrialization of dual-targeted XDC drugs. Drug products include CBP-1008, a drug based on the first-generation bi-XDC technology platform, which is now in clinical phase I/II trials as a monotherapy regimen.

The company raised a series B funding in July 2022, this round of funding will be used for the clinical development of the Bi-XDC pipeline, including the CBP-1008 Chinese pivotal registration phase II clinical trial, CBP-1018 US-China clinical phase I/II trial, CBP-1019 US-China clinical phase I trial, and CBP-8088 (C-PROTAC) US-China IND application.

## Funding rounds

- Series B, May 12, 2023 — Shanghai Alliance Investment, Hefei State-Owned Assets Holding, Hefei High-tech Venture Capital, Shanghai Lianhe Investment, Suzhou Industrial Park Chenrong Venture Capital Co.,Ltd., Park Science and Innovation Fund, Suzhou Industrial Park Science and Technology Innovation Fund, Shengdi Investment
- Series B, Jul 31, 2022 — Harvest Capital, 6 Dimensions Capital, V-Capital, ABC International Investment, HM Capital
- Series A, Nov 15, 2018 — 6 Dimensions Capital
- Series A, Feb 15, 2016 — Frontline BioVentures

## Investors

- Frontline BioVentures (https://capitalatlas.ai/funds/frontline-bioventures) — Series A
- 6 Dimensions Capital (https://capitalatlas.ai/funds/6-dimensions-capital) — Series A, Series B
- Harvest Capital — Series B
- V-Capital (https://capitalatlas.ai/funds/v-capital) — Series B
- ABC International Investment — Series B
- HM Capital (https://capitalatlas.ai/funds/hm-capital) — Series B
- Shanghai Alliance Investment — Series B
- Hefei State-Owned Assets Holding (https://capitalatlas.ai/funds/hefei-state-owned-assets-holding) — Series B
- Hefei High-tech Venture Capital (https://capitalatlas.ai/funds/hefei-high-tech-venture-capital) — Series B
- Shanghai Lianhe Investment — Series B
- Suzhou Industrial Park Chenrong Venture Capital Co.,Ltd. — Series B
- Park Science and Innovation Fund — Series B
- Suzhou Industrial Park Science and Technology Innovation Fund — Series B
- Shengdi Investment — Series B